SN BioScience
SN BioScience is a company founded in 2017 by experts with experience in drug delivery technology, clinical trials, and global clinical development. The company focuses on developing innovative drug delivery systems, especially in nano-medicine, to treat various diseases. It aims to improve clinical outcomes through advanced drug delivery technologies such as liposomes, micelles, and nanoparticles, with a strong emphasis on anticancer and metabolic disease drugs. The company is committed to patient safety, regulatory compliance, and advancing nano-medicine for better healthcare solutions.
Industries
Nr. of Employees
small (1-50)
SN BioScience
#422-Na, LH Business growth center, 54 Changeop-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea (13449)
Patents
Particle and pharmaceutical composition comprising an insoluble camptothecin compound with double core-shell structure and method for manufacturing the same
US-11793803-B2
View DetailsParticle and pharmaceutical composition comprising an insoluble camptothecin compound with double core-shell structure and method for manufacturing the same
US-11793804-B2
View DetailsParticle and pharmaceutical composition comprising an insoluble camptothecin compound with double core-shell structure and method for manufacturing the same
US-10980796-B2
View Details
Particle and pharmaceutical composition comprising an insoluble camptothecin compound with double core-shell structure and method for manufacturing the same
US-11793803-B2
View DetailsParticle and pharmaceutical composition comprising an insoluble camptothecin compound with double core-shell structure and method for manufacturing the same
US-11793804-B2
View DetailsParticle and pharmaceutical composition comprising an insoluble camptothecin compound with double core-shell structure and method for manufacturing the same
US-10980796-B2
View DetailsProducts
SNB-101
Injectable nanoparticle formulation delivering SN-38 (7-ethyl-10-hydroxycamptothecin) using polymeric micelle technology; developed for solid tumors with reported lung tissue penetration.
SNA-001
Albumin-based nanoparticle paclitaxel formulation developed as a generic/alternative manufacturing approach to nab‑paclitaxel; reported scalable, high-yield manufacturing process.
SNA-002
Liposomal sustained-release formulation intended for post-surgical pain management, designed to provide controlled release over multiple days.
SNA-003
Conjugate platform for GLP‑1 receptor agonists and other peptides intended to reduce Cmax/Cmin variability after subcutaneous dosing and improve tolerability for metabolic indications.
SNB-101
Injectable nanoparticle formulation delivering SN-38 (7-ethyl-10-hydroxycamptothecin) using polymeric micelle technology; developed for solid tumors with reported lung tissue penetration.
SNA-001
Albumin-based nanoparticle paclitaxel formulation developed as a generic/alternative manufacturing approach to nab‑paclitaxel; reported scalable, high-yield manufacturing process.
SNA-002
Liposomal sustained-release formulation intended for post-surgical pain management, designed to provide controlled release over multiple days.
SNA-003
Conjugate platform for GLP‑1 receptor agonists and other peptides intended to reduce Cmax/Cmin variability after subcutaneous dosing and improve tolerability for metabolic indications.
Services
Partnerships and joint research for nanomedicine development, including technology transfer and licensing discussions.
Access to laboratory instruments (freeze dryer, optical microscope, DLS, UV–Vis) and coordination of rental of listed equipment.
Partnerships and joint research for nanomedicine development, including technology transfer and licensing discussions.
Access to laboratory instruments (freeze dryer, optical microscope, DLS, UV–Vis) and coordination of rental of listed equipment.
Expertise Areas
- Nanomedicine and drug delivery
- Formulation development for oncology and metabolic diseases
- Preclinical pharmacokinetics and pharmacometrics
- Early-phase clinical trial management
Key Technologies
- Polymeric micelle formulations
- Liposome formulations
- Lipid nanoparticle (LNP) platforms
- Albumin-based nanoparticle formulations
News & Updates
Received FDA Phase 2 IND clearance for SNB-101 targeting small cell lung cancer.
Received FDA Phase 2 IND clearance for SNB-101 targeting small cell lung cancer.